Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fokas

Showing results (251-260 of 329) with videos related to

Pageof 33
Sort By:
Journal of Translational Medicine|May 25, 2019
Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomyC Hoey, M Ahmed, A Fotouhi Ghiam, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2025
Quality of Life After Two Sequences of Total Neoadjuvant Treatment in Patients With Locally Advanced Rectal Cancer in the Randomized CAO/ARO/AIO-12 Phase 2 TrialRebekka Kosmala, Adriana Salazar Hammann, Patrick Paulus, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 23, 2018
Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trialsJens Müller von den Grün, Arndt Hartmann, Rainer Fietkau, et al.
Journal of Cancer Research and Clinical Oncology|February 4, 2021
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapyEike Steidl, Katharina Filipski, Pia S Zeiner, et al.
Cancer Research|November 24, 2011
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculatureEmmanouil Fokas, Jae Hong Im, Sally Hill, et al.
Cancers|September 23, 2022
Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III TrialMarkus Diefenhardt, Daniel Martin, Ethan B Ludmir, et al.
Cancers|August 29, 2024
Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic ModelHanzhi Wang, Linsey Gong, Xiaoyong Huang, et al.
Cancers|December 2, 2020
Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 TrialKatharina J Wenger, Marlies Wagner, Patrick N Harter, et al.
NPJ Precision Oncology|April 23, 2024
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinomaD Martin, F Rödel, S Hehlgans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2014
Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trialEmmanouil Fokas, Torsten Liersch, Rainer Fietkau, et al.
Pageof 33

Showing results (251-260 of 329) with videos related to

Sort By:
Pageof 33
Journal of Translational Medicine|May 25, 2019
Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomyC Hoey, M Ahmed, A Fotouhi Ghiam, et al.
International Journal of Radiation Oncology, Biology, Physics|May 23, 2025
Quality of Life After Two Sequences of Total Neoadjuvant Treatment in Patients With Locally Advanced Rectal Cancer in the Randomized CAO/ARO/AIO-12 Phase 2 TrialRebekka Kosmala, Adriana Salazar Hammann, Patrick Paulus, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 23, 2018
Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trialsJens Müller von den Grün, Arndt Hartmann, Rainer Fietkau, et al.
Journal of Cancer Research and Clinical Oncology|February 4, 2021
A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapyEike Steidl, Katharina Filipski, Pia S Zeiner, et al.
Cancer Research|November 24, 2011
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculatureEmmanouil Fokas, Jae Hong Im, Sally Hill, et al.
Cancers|September 23, 2022
Development and Validation of a Predictive Model for Toxicity of Neoadjuvant Chemoradiotherapy in Rectal Cancer in the CAO/ARO/AIO-04 Phase III TrialMarkus Diefenhardt, Daniel Martin, Ethan B Ludmir, et al.
Cancers|August 29, 2024
Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic ModelHanzhi Wang, Linsey Gong, Xiaoyong Huang, et al.
Cancers|December 2, 2020
Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 TrialKatharina J Wenger, Marlies Wagner, Patrick N Harter, et al.
NPJ Precision Oncology|April 23, 2024
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinomaD Martin, F Rödel, S Hehlgans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2014
Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trialEmmanouil Fokas, Torsten Liersch, Rainer Fietkau, et al.
Pageof 33